16 / 17
Page 41
Notes:
conferenceseries
.com
Volume 5
Journal of Pharmaceutical Care & Health Systems
Pharma Middle East 2018
November 05-07, 2018
November 05-07, 2018 Abu Dhabi, UAE
18
th
Annual
Pharma Middle East Congress
Conclusion:
Association between PPIs use with different doses prior the occurrence of new onset ischemic stroke is insignificant,
after accounting PPIs indications, several factors contributed to the risk of ischemic stroke.
Biography
Maha AlMolaiki has completed her PharmD from King Saud University and has worked assisting as Patient Cares, both in outpatient and inpatient at King Abdulaziz
Medical City-Central region. She is currently a Pharma Resident at Pharmacy Residency at King Abdulaziz Medical City-Central Region.
Almolaikima@ngha.med.saInclusion criteria:
Patients 25 years or older with/without a medical history of hypertension, diabetes, dyslipidaemia, ischemic heart disease, heart failure,
myocardial infarction, atrial fibrillation, chronic kidney disease on haemodialysis or peritoneal dialysis, who were using anticoagulant and
nonsteroidal anti-inflammatory medications.
Exclusion criteria:
Patients with history of ischemic stroke, transient ischemic attack, haemorrhagic stroke, neurological diseases, brain tumor, encephalitis,
meningitis, pregnant women.
Primary endpoint:
To assess the association between PPIs use and the risk of development new onset ischemic stroke.
Secondary endpoint:
To determine the relationship between dose and frequency of PPIs and development of new onset ischemic stroke.